The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to expand the research scope and leverage the gains made through the “Investigation of the Transmission of KSHV” initiatives (RFA-CA-18-013 and RFA-CA-20-046) to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such multicentric Castleman disease (MCD), primary effusion lymphoma (PEL) and KSHV inflammatory cytokine syndrome (KICS) or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people who are already infected with KSHV.
This Notice is being provided to allow potential applicants time to develop responsive projects and meaningful collaborations. The NOFO is expected to use the U01This Notice encourages investigators with expertise and insights into the area of Kaposi sarcoma-associated herpesvirus (KSHV) and/or vaccine development to begin to consider applying for this new NOFO.
Estimated Publication Date of Notice of Funding Opportunity: October 02, 2023
First Estimated Application Due Date: December 14, 2023
For more information: https://grants.nih.gov/grants/guide/notice-files/NOT-CA-23-067.html